Search

Memorial Sloan Kettering has announced the creation of the Louis V. Gerstner, Jr. Young Investigators Fund and has named the fund's first four recipients.

… Friday, May 1, 2009 Summary Memorial Sloan Kettering has announced the creation of the Louis V. Gerstner, Jr. Young Investigators Fund and has named the fund’s first four recipients. Memorial Sloan Kettering has announced the creation of the Louis V. Gerstner, Jr. Young Investigators Fund and has named

Researchers found that a common cancer gene called PIK3CA also causes the condition venous malformation. Their discovery has already pointed the way to targeted therapies for this rare and painful condition that affects one in 10,000 people.

… Wednesday, March 30, 2016 Summary MSK researchers have made a surprising finding: A common cancer gene called PIK3CA also causes the condition venous malformation. Their discovery has already pointed the way to targeted therapies for this rare and painful condition that affects one in 10,000 people.

Meet MSK Research Scholar Moralba Dominguez Garcia, PhD: “I wanted to do something that creates knowledge — and that can help other people.”

… Friday, June 6, 2025 For Moralba (Mora) Dominguez Garcia, PhD , being a Research Scholar developing radiopharmaceuticals against cancer is a dream come true.  Like so many trainees who come to Memorial Sloan Kettering Cancer Center (MSK) from around the world after earning a PhD, she was drawn by the

Learn how HPV-related head and neck cancer can be treated with a sharply reduced radiation dose to prevent side effects, sometimes without surgery.

… Friday, September 20, 2024 An innovative radiation treatment approach that is typically given to patients after surgical removal of HPV-positive head and neck tumors may now help some of those patients avoid surgery altogether.  The approach, pioneered by Memorial Sloan Kettering Cancer Center (MSK)

A new analysis of survival data for the randomized, phase III PACIFIC trial finds adding the immunotherapy cancer drug durvalumab to radiation and chemotherapy significantly decreased the recurrence of lung cancer both in the chest area and in distant sites outside the chest. The updated PACIFIC trial data will be presented at the 61st Annual Meeting of the American Society for Radiation Oncology (ASTRO), by Andreas Rimner, MD, radiation oncologist, Memorial Sloan Kettering Cancer Center.

… Monday, September 16, 2019 Bottom Line: A new analysis of survival data for the randomized, phase III PACIFIC trial finds adding the immunotherapy cancer drug durvalumab to radiation and chemotherapy significantly decreased the recurrence of lung cancer both in the chest area and in distant sites outside

Sloan Kettering Institute scientists are using zebrafish to understand human skin cancer that attacks the hands and feet.

… Wednesday, March 30, 2022 To understand cancer in humans, researchers at the Sloan Kettering Institute (SKI) are turning to our distant relatives from 425 million years ago: fish. A lot has evolved since then: Fish use their fins to swim, whereas we use our hands to play Wordle. But there remains a deep

Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments.

… Thursday, August 29, 2024 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: David Jones Appointed the 105 th President of the American Association for Thoracic Surgery David Jones, MD David Jones, MD , thoracic surgeon, chief of the Thoracic Service,

A retrospective study by urologists at MSKCC and their colleagues, suggests that this practice needs to be re-evaluated. Researchers add that with advances in imaging, almost 70 percent of kidney cancer patients have their tumor detected at a very small size allowing surgeons to perform less radical surgery with superior results.

… Tuesday, September 5, 2006 For forty years, the gold standard for treating a single, small tumor in the kidney has been to remove the entire kidney. A retrospective study, which appears in the September issue of The Lancet Oncology, by urologists at Memorial Sloan Kettering Cancer Center (MSKCC) and

Treating people with advanced metastatic kidney cancer using a combination of the immunotherapy drugs nivolumab (Opdivo®) and ipilimumab (Yervoy®) significantly increased overall survival versus treatment with sunitinib (Sutent®) alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) that were reported online today in the New England Journal of Medicine.

… Wednesday, March 21, 2018 Treating people with advanced metastatic kidney cancer using a combination of the immunotherapy drugs nivolumab (Opdivo ® ) and ipilimumab (Yervoy ® ) significantly increased overall survival versus treatment with sunitinib (Sutent ® ) alone, according to new findings from researchers

An FDA-approved drug used to treat leukemia can serve as a temporary off switch for CAR T cells, MSK scientists have found.

… Wednesday, July 3, 2019 Summary Researchers at Memorial Sloan Kettering and University Hospital in Würzburg, Germany, have identified a simple way to temporarily switch off CAR T cells with a commonly used drug. The approach could potentially help doctors limit the sometimes-severe side effects of this